Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million...
Scienture Holdings: Q2 Earnings Snapshot
Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™ Targeting continued commercial...
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray U.S. naloxone market totals ~$144 million in annual...
Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth COMMACK, NY, June 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE...
Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market U.S. naloxone market totals ~$144 million in annual sales...
U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for...
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing...
Scienture Holdings: Q1 Earnings Snapshot
Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment Financing...